

24 December 2019

Update on Second Subscription Placement

EVE Investments (ASX:EVE), an ASX listed health, nutrition and wellness company today provides an update on the placement announced to the ASX on 7 October 2019.

Given the Christmas holiday period EVE has agreed with both subscription parties, Everhoney Biotech Australia Pty Ltd (“Everhoney”) and Hong Kong Jusheng Bolang Technology Co., Limited (“Jusheng Bolang”) to extend the deadline for the Second Subscription to 15 January 2020. The Second Subscription will see both parties collectively subscribing for \$6,888,986 at \$0.01/share.

Both parties, completed their First Subscription commitments in early December, raising \$2,411,145 at \$0.005, with both subscriptions being approved at the Company’s 2019 Annual General Meeting.

Authorised for release by Bill Fry, Managing Director

For more information:

Bill Fry
Managing Director
Eve Investments Ltd
+61 8 6465 5500
billf@eveinvestments.com.au

About EVE Investments

EVE Investments invests in companies with a focus on the medical nutrition and wellness sector. The Company’s investment strategy has a three pronged approach.

1. To invest in businesses that are in the early growth phase with the aim to support their expansion programs.
2. To identify products that have unique medicinal properties and a global reach application.
3. Preference for natural organic products that have demonstrated medicinal benefits.

For further information, please visit www.eveinvestments.com.au and follow us on Twitter [@EVEInvestments](https://twitter.com/EVEInvestments)